Zymeworks Q1 Revenue Plunges, Missing Estimates by Over 85% on Milestone Payment Absence
summarizeSummary
Zymeworks reported a significant Q1 revenue miss, coming in at $2.4 million against analyst estimates of $16.26 million, an over 85% shortfall. The company also missed EPS expectations, reporting -$0.59 versus a -$0.19 consensus. The substantial revenue decline was primarily attributed to the absence of non-recurring milestone payments received in the prior-year period. While the company reiterated its guidance for adjusted gross operating expenses and expects existing cash and future milestone payments to fund operations beyond 2028, the immediate and large earnings miss is a material negative surprise for traders. This news follows the company's recent $250 million non-recourse loan from Royalty Pharma, which had previously extended its cash runway. Investors will now focus on future milestone payment potential and the impact of the company's reduced operating expenses, alongside the recently announced $95.8 million share repurchase.
At the time of this announcement, ZYME was trading at $26.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.86 to $29.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.